<p>Posaconazole is indicated in patients aged 13 years and above for the treatment of the following fungal infections:</p>

<ul>
	<li>Invasive aspergillosis in patients with disease that is refractory or intolerant to Amphotericin B or Itraconazole</li>
	<li>Fusariosis in patients with disease that is refractory or intolerant to Amphotericin B</li>
	<li>Chromoblastomycosis and mycetoma in patients with disease that is refractory or intolerant to Itraconazole</li>
	<li>Coccidioidomycosis in patients with disease that is refractory or intolerant to Amphotericin B, Itraconazole or Fluconazole or in patients who are intolerant of these medicinal products.</li>
</ul>

<p>Also indicated for prophylaxis of invasive fungal infections in the following patients:</p>

<ul>
	<li>Patients receiving remission-induction chemotherapy for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections</li>
	<li>Hematopoietic Stem Cell Transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy</li>
</ul>